ARCT - Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch
You'd nearly have to live in a cave to not hear about the major advances for the leading coronavirus vaccines. Pfizer and BioNTech have already won authorization in the U.K. for their vaccine, BNT162b2, which could receive U.S. emergency use authorization within weeks. So could Moderna 's mRNA-1273.
There are other companies that could be hot on their heels. AstraZeneca hopes to soon score approvals for AZD1222. Johnson & Johnson should announce interim late-stage study results for its vaccine candidate JNJ-78436735 in early 2021. Novavax anticipates reporting results from its U.K. late-stage study of NVX-CoV2373 early next year and looks forward to kicking off a late-stage study in the U.S. within the next few weeks.
It's completely understandable why these companies are the center of attention right now. However, there's also a dark horse in the COVID-vaccine race that you'll want to watch -- Arcturus Therapeutics (NASDAQ: ARCT) .
For further details see:
Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch